文献速递白血病造血干细胞移植与细胞治疗

现货型双靶点CAR-iNKT细胞免疫疗法根除髓内及脑膜高危KMT2A重排白血病

Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia.
PubMed 文献 · Blood · 2026-01-01

研究在体外和体内模型中评估CD19和/或CD133靶向CAR-iNKT细胞对KMT2A重排急性淋巴细胞白血病的抗白血病活性,发现双特异性CD19-CD133 CAR-iNKT细胞较单靶点CAR-iNKT及双特异性CAR-T细胞抗白血病活性更强,可根除髓内及脑膜白血病并诱导持续缓解,机制涉及NKG2D上调。

要点

  • 双特异性CD19-CD133 CAR-iNKT细胞抗白血病活性强于单靶点CAR-iNKT及双特异性CAR-T细胞。
  • 双特异性CAR-iNKT细胞根除髓内及脑膜白血病,诱导持续缓解,无明显血液学毒性。
  • CAR-iNKT细胞通过CAR依赖且CAR抗原依赖的NKG2D上调增强抗白血病效应。

核心结论

  • 双特异性CD19-CD133 CAR-iNKT细胞通过同时靶向CAR抗原和NKG2D配体,为KMT2Ar-ALL提供强效治疗平台。

研究设计与样本

  • 研究在相关体外和体内模型中评估CD19和/或CD133靶向CAR-iNKT细胞对KMT2Ar-ALL的抗白血病活性。

主要发现

  • 与单靶点CAR-iNKT细胞和双特异性CAR-T细胞相比,双特异性CD19-CD133 CAR-iNKT细胞抗白血病活性更强,有效靶向CAR抗原高表达和低表达白血病。
  • 双特异性CAR-iNKT细胞根除髓内及脑膜白血病,诱导持续缓解,无明显血液学毒性。
  • CAR-iNKT细胞较CAR-T细胞更强的抗白血病效应由CAR依赖且CAR抗原依赖的NKG2D显著上调及其与KMT2Ar-ALL细胞相应配体结合所介导,确保CD133或CD19下调时仍有效靶向白血病。

关键数值与推荐

  • 双特异性CD19-CD133 CAR-iNKT细胞较单靶点CAR-iNKT细胞和双特异性CAR-T细胞抗白血病活性更强。
  • 双特异性CAR-iNKT细胞根除髓内及脑膜白血病,诱导持续缓解,无明显血液学毒性。

临床怎么用

  • 作者认为CAR-iNKT细胞通过结合CAR抗原和NKG2D配体两类白血病相关抗原,为KMT2Ar-ALL治疗提供强效平台。
  • 作者认为该方法可适用于其他高危恶性肿瘤,包括难以靶向的脑膜受累者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Current therapies, including autologous chimeric antigen receptor (CAR) T-cell immunotherapy, fail to cure half of infants with KMT2A-rearranged acute lymphoblastic leukemia (KMT2Ar-ALL), a disease characterized by frequent central nervous system involvement, poor treatment response, early relapse, and lineage switching. More effective treatment strategies, including the availability of off-the-shelf immunotherapies, is particularly relevant in infants. PROM1/CD133 is a direct target of KMT2A-fusion oncoproteins and is expressed on leukemic cells. Allogeneic invariant natural killer T (iNKT) cells, "innately" more powerful effectors than T cells, can be deployed off-the-shelf without risk of acute graft-versus-host disease. Here, we equip iNKT cells with CD19- and/or CD133-targeting CARs, and investigate their antileukemia activity against KMT2Ar-ALL in relevant in vitro and in vivo models. Compared with monospecific counterparts and dual, bispecific CAR T cells, bispecific CD19-CD133 CAR-iNKT cells have a more potent antileukemia activity, effectively targeting both CAR antigen-high and -low leukemia. Bispecific CAR-iNKT cells eradicate medullary and, notably, leptomeningeal leukemia, and induce sustained remissions without discernible hematologic toxicity. Mechanistically, the more potent antileukemia effect of CAR-iNKT cells over CAR T cells is mediated by a pronounced CAR-dependent and CAR antigen-dependent upregulation of the innate activating receptor NKG2D on CAR-iNKT cells, and its engagement by its corresponding ligands on KMT2Ar-ALL cells. This ensures effective leukemia targeting even with downregulation of CD133 or CD19. Thus, by engaging with 2 different types of leukemia-associated antigens, that is, CAR antigens and NKG2D ligands, CAR-iNKT cells provide a powerful platform for the treatment of KMT2Ar-ALL. This approach can be readily adapted for other high-risk malignancies, including those with otherwise difficult to target leptomeningeal involvement.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Ren H, Elliott N, Lye B, et al. Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia. Blood. 2026. PMID: 40898981. doi:10.1182/blood.2025029302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。